Drug intelligence / Profile preview

CBP-403

Development stage: Preclinical
Lead developer: Connect Biopharma
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

CBP-403 is a bispecific monoclonal antibody developed by Suzhou Connect Biopharma. It is designed as an inhibitor of T helper 2 (Th2) cells, targeting Th2 cytokines to modulate type 2 inflammatory responses. The drug's primary therapeutic focus is on inflammatory diseases, leveraging its novel mechanism of action to inhibit pathways central to Th2-driven inflammation. As of the latest available information, CBP-403 has reached preclinical development and has not advanced into clinical trials or received regulatory approval[1][6][2].

Beyond the preview

Go deeper on CBP-403.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CBP-403.

Explore the full profile